vs
Side-by-side financial comparison of Atara Biotherapeutics, Inc. (ATRA) and KOSS CORP (KOSS). Click either name above to swap in a different company.
KOSS CORP is the larger business by last-quarter revenue ($2.9M vs $1.6M, roughly 1.8× Atara Biotherapeutics, Inc.). On growth, KOSS CORP posted the faster year-over-year revenue change (-19.6% vs -95.1%). Over the past eight quarters, KOSS CORP's revenue compounded faster (4.2% CAGR vs -75.9%).
Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic T-cell immunotherapies for patients with unmet medical needs across oncology, autoimmune disease, and infectious disease indications. It operates primarily in North America, Europe, and Asia-Pacific, partnering with research institutions to advance its novel treatment pipeline.
Koss Corporation is a company in Milwaukee, Wisconsin, US that manufactures headphones. The company created the first high-fidelity stereo headphones in 1958.
ATRA vs KOSS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $2.9M |
| Net Profit | — | $-565.4K |
| Gross Margin | — | 29.0% |
| Operating Margin | — | -35.5% |
| Net Margin | — | -19.8% |
| Revenue YoY | -95.1% | -19.6% |
| Net Profit YoY | 73.2% | -700.6% |
| EPS (diluted) | — | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $2.9M | ||
| Q3 25 | $3.5M | $4.1M | ||
| Q2 25 | $17.6M | $3.1M | ||
| Q1 25 | $98.1M | $2.8M | ||
| Q4 24 | $32.8M | $3.6M | ||
| Q3 24 | $40.2M | $3.2M | ||
| Q2 24 | $28.6M | $2.9M | ||
| Q1 24 | $27.4M | $2.6M |
| Q4 25 | — | $-565.4K | ||
| Q3 25 | $-4.3M | $243.7K | ||
| Q2 25 | $2.4M | $-232.7K | ||
| Q1 25 | $38.0M | $-316.7K | ||
| Q4 24 | $-12.7M | $94.1K | ||
| Q3 24 | $-21.9M | $-419.5K | ||
| Q2 24 | $-19.0M | $-110.4K | ||
| Q1 24 | $-31.8M | $-313.8K |
| Q4 25 | — | 29.0% | ||
| Q3 25 | — | 40.0% | ||
| Q2 25 | — | 36.0% | ||
| Q1 25 | — | 39.0% | ||
| Q4 24 | — | 39.5% | ||
| Q3 24 | — | 36.6% | ||
| Q2 24 | — | 40.4% | ||
| Q1 24 | — | 31.9% |
| Q4 25 | — | -35.5% | ||
| Q3 25 | -103.5% | -1.1% | ||
| Q2 25 | 18.2% | -14.2% | ||
| Q1 25 | 39.5% | -18.7% | ||
| Q4 24 | -37.3% | -4.0% | ||
| Q3 24 | -54.1% | -19.9% | ||
| Q2 24 | -63.7% | -11.0% | ||
| Q1 24 | -114.2% | -23.1% |
| Q4 25 | — | -19.8% | ||
| Q3 25 | -124.6% | 6.0% | ||
| Q2 25 | 13.6% | -7.5% | ||
| Q1 25 | 38.7% | -11.4% | ||
| Q4 24 | -38.8% | 2.6% | ||
| Q3 24 | -54.5% | -13.1% | ||
| Q2 24 | -66.5% | -3.8% | ||
| Q1 24 | -116.1% | -11.9% |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | $-0.32 | $0.03 | ||
| Q2 25 | $0.19 | $-0.02 | ||
| Q1 25 | $3.50 | $-0.03 | ||
| Q4 24 | $0.27 | $0.01 | ||
| Q3 24 | $-2.93 | $-0.05 | ||
| Q2 24 | $-3.10 | $-0.01 | ||
| Q1 24 | $-5.65 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $15.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-38.5M | $30.3M |
| Total Assets | $20.2M | $36.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $15.5M | ||
| Q3 25 | $13.7M | $16.5M | ||
| Q2 25 | $22.3M | $15.7M | ||
| Q1 25 | $13.8M | $13.0M | ||
| Q4 24 | $42.5M | $9.7M | ||
| Q3 24 | $67.2M | $11.9M | ||
| Q2 24 | $35.3M | $14.9M | ||
| Q1 24 | $46.2M | $9.9M |
| Q4 25 | $-38.5M | $30.3M | ||
| Q3 25 | $-36.6M | $30.9M | ||
| Q2 25 | $-35.0M | $30.6M | ||
| Q1 25 | $-55.1M | $30.7M | ||
| Q4 24 | $-97.3M | $31.0M | ||
| Q3 24 | $-90.5M | $30.8M | ||
| Q2 24 | $-110.9M | $31.1M | ||
| Q1 24 | $-98.3M | $31.1M |
| Q4 25 | $20.2M | $36.8M | ||
| Q3 25 | $30.2M | $37.7M | ||
| Q2 25 | $36.9M | $37.2M | ||
| Q1 25 | $62.0M | $37.3M | ||
| Q4 24 | $109.1M | $37.4M | ||
| Q3 24 | $142.7M | $38.1M | ||
| Q2 24 | $117.3M | $37.2M | ||
| Q1 24 | $165.3M | $37.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-50.9M | $-760.8K |
| Free Cash FlowOCF − Capex | — | $-1.1M |
| FCF MarginFCF / Revenue | — | -37.5% |
| Capex IntensityCapex / Revenue | 0.0% | 10.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-546.7K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-50.9M | $-760.8K | ||
| Q3 25 | $-9.8M | $762.6K | ||
| Q2 25 | $-7.3M | $-534.9K | ||
| Q1 25 | $-28.1M | $370.4K | ||
| Q4 24 | $-24.5M | $-252.0K | ||
| Q3 24 | $-4.0M | $201.6K | ||
| Q2 24 | $-10.6M | $-174.0K | ||
| Q1 24 | $-29.6M | $328.6K |
| Q4 25 | — | $-1.1M | ||
| Q3 25 | — | $761.5K | ||
| Q2 25 | — | $-541.8K | ||
| Q1 25 | — | $306.2K | ||
| Q4 24 | $-24.6M | $-314.3K | ||
| Q3 24 | — | $-155.6K | ||
| Q2 24 | $-10.7M | $-174.8K | ||
| Q1 24 | $-29.7M | $269.3K |
| Q4 25 | — | -37.5% | ||
| Q3 25 | — | 18.7% | ||
| Q2 25 | — | -17.6% | ||
| Q1 25 | — | 11.0% | ||
| Q4 24 | -75.0% | -8.8% | ||
| Q3 24 | — | -4.9% | ||
| Q2 24 | -37.3% | -6.0% | ||
| Q1 24 | -108.7% | 10.2% |
| Q4 25 | 0.0% | 10.9% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 2.3% | ||
| Q4 24 | 0.3% | 1.8% | ||
| Q3 24 | 0.0% | 11.2% | ||
| Q2 24 | 0.1% | 0.0% | ||
| Q1 24 | 0.5% | 2.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 3.13× | ||
| Q2 25 | -3.07× | — | ||
| Q1 25 | -0.74× | — | ||
| Q4 24 | — | -2.68× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
